Please provide your email address to receive an email when new articles are posted on . The accompanying cover story summarizes some pioneering activities in collagen cross-linking for keratoconus. In ...
Epioxa, an epithelium-on corneal collagen cross-linking therapy, made a significant and clinically meaningful difference in ...
SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...
A study published in Ophthalmology and Therapy found that Epioxa, an epithelium-on corneal collagen cross-linking treatment, ...
Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
(MASS APPEAL) – If you’ve been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight. Mass Appeal’s Patrick Berry joined Dr. John P. Frangie, MD to learn more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results